Use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies - Scientific guideline
Table of contents
This document describes the basis and regulatory requirements for the use of minimal residue disease as an intermediate endpoint to predict clinical benefit in trials in chronic lymphocytic leukaemia.
Keywords: Minimal residual disease (MRD), chronic lymphocytic leukaemia (CLL)